[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20160194A1 - Composiciones y metodos para tratar anemia - Google Patents

Composiciones y metodos para tratar anemia

Info

Publication number
PE20160194A1
PE20160194A1 PE2015002603A PE2015002603A PE20160194A1 PE 20160194 A1 PE20160194 A1 PE 20160194A1 PE 2015002603 A PE2015002603 A PE 2015002603A PE 2015002603 A PE2015002603 A PE 2015002603A PE 20160194 A1 PE20160194 A1 PE 20160194A1
Authority
PE
Peru
Prior art keywords
compositions
methods
alkyl
formula
pharmaceutically acceptable
Prior art date
Application number
PE2015002603A
Other languages
English (en)
Inventor
Akshay Buch
Joseph Gardner
Isaiah Shalwitz
John Janusz
Robert Shalwitz
Charlotte Hartman
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52022903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160194(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of PE20160194A1 publication Critical patent/PE20160194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente dosis especificas de, y regimenes de dosificacion para utilizar un inhibidor de la HIF prolil hidroxilasa en el tratamiento o prevencion de anemia, el inhibidor de HIF prolil hidroxilasa es el acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}-acetico o una sal, solvato, o hidrato farmaceuticamente aceptable del mismo, de formula (I), denominado tambien como VADADUSTAT(AKB-6548), asimismo provee una composicion farmaceutica, caracterizada porque comprende un compuesto de que tiene la formula (V); o una sal o tautomero farmaceuticamente aceptable del mismo, en donde L es alquilo de C1-6 ; y en donde R1 y R2 son independientemente H o alquilo de C1-6
PE2015002603A 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia PE20160194A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361834808P 2013-06-13 2013-06-13
US201361889478P 2013-10-10 2013-10-10
US201361898890P 2013-11-01 2013-11-01
US201361898885P 2013-11-01 2013-11-01
US201361912185P 2013-12-05 2013-12-05

Publications (1)

Publication Number Publication Date
PE20160194A1 true PE20160194A1 (es) 2016-04-20

Family

ID=52022903

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015002603A PE20160194A1 (es) 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia
PE2020000452A PE20201496A1 (es) 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020000452A PE20201496A1 (es) 2013-06-13 2014-06-04 Composiciones y metodos para tratar anemia

Country Status (37)

Country Link
US (2) US11857543B2 (es)
EP (2) EP4360706A3 (es)
JP (5) JP2016521747A (es)
KR (4) KR102373245B1 (es)
CN (3) CN114404413A (es)
AU (4) AU2014278543B2 (es)
BR (1) BR112015031027A2 (es)
CA (2) CA2914662C (es)
CL (2) CL2015003602A1 (es)
CY (2) CY1126699T1 (es)
DK (1) DK3007695T3 (es)
DO (1) DOP2015000297A (es)
EC (1) ECSP20058592A (es)
ES (1) ES2974273T3 (es)
FI (2) FI3007695T3 (es)
FR (1) FR24C1025I2 (es)
HR (1) HRP20240319T1 (es)
HU (2) HUE066123T2 (es)
IL (3) IL243047B (es)
LT (1) LT3007695T (es)
MX (3) MX378150B (es)
MY (1) MY204336A (es)
NL (1) NL301278I2 (es)
NO (1) NO2024025I1 (es)
NZ (3) NZ714963A (es)
PE (2) PE20160194A1 (es)
PH (2) PH12015502738B1 (es)
PL (1) PL3007695T3 (es)
PT (1) PT3007695T (es)
RS (1) RS65341B1 (es)
RU (2) RU2019134558A (es)
SG (2) SG11201509998WA (es)
SI (1) SI3007695T1 (es)
SM (1) SMT202400092T1 (es)
TW (5) TWI791177B (es)
WO (1) WO2014200773A2 (es)
ZA (1) ZA201509024B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327696A1 (en) 2006-06-26 2011-06-01 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (es) 2011-06-06 2018-03-17
EP2986207B1 (en) 2013-04-16 2024-03-20 Koninklijke Philips N.V. System and method for biventricular pacemaker pulse detection in surface ecg
LT3007695T (lt) * 2013-06-13 2024-03-25 Akebia Therapeutics, Inc. Kompozicijos ir būdai, skirti anemijos gydymui
RU2021125455A (ru) 2013-11-15 2021-10-05 Экебиа Терапьютикс, Инк. Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
MX374909B (es) * 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
CN108401429A (zh) * 2016-12-06 2018-08-14 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
TWI822776B (zh) 2018-05-09 2023-11-21 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
BR112022008484A2 (pt) 2019-10-31 2022-07-19 Akebia Therapeutics Inc Método de tratamento de anemia, método para aumentar os níveis de hemoglobina em um paciente com anemia associada ou secundária à doença renal crônica e método para manter ou controlar os níveis de hemoglobina em um paciente com anemia associada ou secundária à doença renal crônica
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
TW202206065A (zh) * 2020-04-29 2022-02-16 美商百愛及生物醫藥公司 用以治療老化相關病況之缺氧誘導因子脯胺醯羥化酶抑制劑
JP2023530452A (ja) 2020-06-19 2023-07-18 アケビア セラピューティクス インコーポレイテッド バダデュスタットの薬物間相互作用の調節
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
JP2024503377A (ja) 2021-01-08 2024-01-25 アケビア セラピューティクス インコーポレイテッド バダデュスタットを使用した治療方法
AU2022229275A1 (en) 2021-03-01 2023-10-12 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
DK0650960T3 (da) 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
AU5762896A (en) 1996-04-30 1997-11-19 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE273277T1 (de) 1998-03-23 2004-08-15 Aventis Pharma Inc Piperidinyl- und n-amidinopiperidinyl-derivate
GB9809213D0 (en) 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6177101B1 (en) 1998-06-11 2001-01-23 Pharmacia & Upjohn Company Delavirdine high strength tablet formulation
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
MXPA03006217A (es) 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP2298301B2 (en) * 2001-12-06 2022-11-16 Fibrogen, Inc. Medicaments for treating anemia associated with kidney disease
CA2486141A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
BR0313239A (pt) 2002-08-29 2005-06-14 Merck & Co Inc Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
CA2502541A1 (en) 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
WO2004048383A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CN102977015B (zh) 2003-06-06 2015-05-06 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
ATE443775T1 (de) 2004-05-28 2009-10-15 Fibrogen Inc Hif-prolylhydroxylase-aktivitätstest
TW200609218A (en) 2004-05-31 2006-03-16 Tanabe Seiyaku Co Bicyclic compounds
BRPI0511834A (pt) 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
JP5410751B2 (ja) 2005-06-15 2014-02-05 ファイブローゲン、インコーポレーテッド がん治療のための化合物および方法
RU2424805C2 (ru) 2005-09-12 2011-07-27 Актелион Фармасьютиклз Лтд Стабильные фармацевтические композиции, включающие пиримидинсульфамид
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
WO2007081835A2 (en) 2006-01-09 2007-07-19 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
KR100798730B1 (ko) * 2006-06-12 2008-01-29 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
EP2327696A1 (en) * 2006-06-26 2011-06-01 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
GB2444904B (en) 2006-12-05 2008-11-05 Michael Hilary Burke A Process For The Preparation of an Orally Administrable Unit Dose Tablet
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CA2682929A1 (en) 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
CN101663037A (zh) 2007-04-18 2010-03-03 默克公司 新的1,8-二氮杂萘化合物
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
JP5349462B2 (ja) 2007-05-16 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション スピロインダロン
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009020119A1 (ja) 2007-08-06 2009-02-12 Senju Pharmaceutical Co., Ltd. ＨＩＦ－１αおよびＨＩＦ－２α発現阻害物質含有医薬
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US20110028507A1 (en) 2007-08-10 2011-02-03 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
CN102099335A (zh) 2008-07-23 2011-06-15 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
TW201006473A (en) * 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
AU2009290365B2 (en) 2008-09-15 2014-08-14 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
US8137666B2 (en) * 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
LT2732818T (lt) 2009-03-31 2017-09-25 Ligand Pharmaceuticals Inc. Endotelino ir angiotenzino ii receptorių bifenilsulfonamido antagonistai, skirti glomerulosklerozės gydymui
WO2010113942A1 (ja) 2009-03-31 2010-10-07 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途
HRP20140705T1 (hr) 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
ES2533128T3 (es) 2009-11-06 2015-04-07 Aerpio Therapeutics Inc. Inhibidores de la prolilhidroxilasa
US20140171465A1 (en) 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
NO2686520T3 (es) 2011-06-06 2018-03-17
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
LT3007695T (lt) * 2013-06-13 2024-03-25 Akebia Therapeutics, Inc. Kompozicijos ir būdai, skirti anemijos gydymui
CA2921005A1 (en) 2013-08-16 2015-02-19 Ohio State Innovation Foundation Compositions and methods for modulating dna methylation
RU2021125455A (ru) 2013-11-15 2021-10-05 Экебиа Терапьютикс, Инк. Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
EP3096617A4 (en) 2014-01-23 2017-09-13 Akebia Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
AU2016235534A1 (en) 2015-03-20 2017-10-12 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
MX374909B (es) 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
EP3860593A1 (en) 2018-10-03 2021-08-11 Akebia Therapeutics Inc. Benzimidazole derivative for use in the treatment of inflammatory disorders
US11524939B2 (en) * 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
SG10201910773VA (en) 2020-01-30
EP3007695A2 (en) 2016-04-20
CL2015003602A1 (es) 2016-07-29
CN105451739A (zh) 2016-03-30
WO2014200773A3 (en) 2015-03-05
MX2022003510A (es) 2022-05-16
TW202446394A (zh) 2024-12-01
CY2024016I2 (el) 2025-05-09
KR102461176B1 (ko) 2022-11-01
AU2014278543B2 (en) 2019-11-14
JP6612479B2 (ja) 2019-11-27
CY2024016I1 (el) 2025-05-09
TWI712411B (zh) 2020-12-11
IL281058B1 (en) 2023-04-01
DK3007695T3 (da) 2024-03-18
SI3007695T1 (sl) 2024-04-30
KR20240055172A (ko) 2024-04-26
JP6937812B2 (ja) 2021-09-22
KR20220151008A (ko) 2022-11-11
DOP2015000297A (es) 2016-03-15
IL281058A (en) 2021-04-29
ZA201509024B (en) 2019-05-29
RU2016100363A (ru) 2017-07-18
NZ753905A (en) 2020-07-31
NL301278I2 (nl) 2024-08-01
CN114404414A (zh) 2022-04-29
MY204336A (en) 2024-08-23
FR24C1025I1 (fr) 2024-07-26
HK1216844A1 (en) 2016-12-09
KR20160023773A (ko) 2016-03-03
PE20201496A1 (es) 2020-12-29
JP2023145717A (ja) 2023-10-11
RU2019134558A (ru) 2020-02-20
ES2974273T3 (es) 2024-06-26
PL3007695T3 (pl) 2024-07-01
US20160143891A1 (en) 2016-05-26
PH12020551705A1 (en) 2021-11-15
US20240335434A1 (en) 2024-10-10
HRP20240319T1 (hr) 2024-05-24
FR24C1025I2 (fr) 2025-06-20
LT3007695T (lt) 2024-03-25
TWI856464B (zh) 2024-09-21
SMT202400092T1 (it) 2024-05-14
TWI791177B (zh) 2023-02-01
AU2014278543A1 (en) 2016-01-07
IL281058B2 (en) 2023-08-01
ECSP20058592A (es) 2020-10-30
KR20210043760A (ko) 2021-04-21
JP7328291B2 (ja) 2023-08-16
NO2024025I1 (no) 2024-05-29
MX2020006963A (es) 2022-03-30
AU2024205219A1 (en) 2024-09-19
TW201922244A (zh) 2019-06-16
IL270335B (en) 2021-03-25
PH12015502738A1 (en) 2016-03-07
US11857543B2 (en) 2024-01-02
IL243047B (en) 2019-11-28
FIC20240023I1 (fi) 2024-06-25
TW201534302A (zh) 2015-09-16
KR102660040B1 (ko) 2024-04-24
PH12015502738B1 (en) 2021-12-10
JP2019163293A (ja) 2019-09-26
CL2018002372A1 (es) 2018-12-28
BR112015031027A2 (pt) 2017-08-29
JP7672455B2 (ja) 2025-05-07
NZ753904A (en) 2020-07-31
HUS2400023I1 (hu) 2024-07-28
AU2022200570A1 (en) 2022-02-17
EP3007695B1 (en) 2024-02-07
JP2021191773A (ja) 2021-12-16
NZ714963A (en) 2020-07-31
AU2020200903A1 (en) 2020-02-27
HUE066123T2 (hu) 2024-07-28
TW202339743A (zh) 2023-10-16
CA2914662A1 (en) 2014-12-18
AU2022200570B2 (en) 2024-05-02
MX378150B (es) 2025-03-10
CA3151685A1 (en) 2014-12-18
CN114404413A (zh) 2022-04-29
FI3007695T3 (fi) 2024-03-13
WO2014200773A2 (en) 2014-12-18
TWI650126B (zh) 2019-02-11
MX2015017229A (es) 2016-04-19
MX391198B (es) 2025-03-21
AU2020200903B2 (en) 2021-11-04
JP2016521747A (ja) 2016-07-25
CA2914662C (en) 2022-05-31
SG11201509998WA (en) 2016-01-28
EP4360706A2 (en) 2024-05-01
EP4360706A3 (en) 2024-07-10
CY1126699T1 (el) 2025-05-09
TW202133843A (zh) 2021-09-16
KR102373245B1 (ko) 2022-03-17
JP2020033369A (ja) 2020-03-05
RS65341B1 (sr) 2024-04-30
PT3007695T (pt) 2024-03-07
RU2016100363A3 (es) 2018-05-15
RU2705206C2 (ru) 2019-11-06
EP3007695A4 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
PE20160194A1 (es) Composiciones y metodos para tratar anemia
AR085668A1 (es) Terapias combinadas para malignidades hematologicas
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
EA201690989A1 (ru) Ингибиторы syk
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
MX2016001427A (es) Inhibidores de syk.
PE20142186A1 (es) Derivados biciclicos de pirazinona
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201690277A1 (ru) Производные замещенного глиоксамидом пирроламида и их применение в качестве лекарственных средств для лечения гепатита b
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
MD20140047A2 (ro) Inhibitori ai protein kinazei
NZ726366A (en) Syk inhibitors
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis